DrugDev.org, a global interactive network of clinical trial doctors –presented its Insiders’ Site ID and Study StartUp Report at DIA 2012. Key results from the survey of over 220 project managers from large pharma, small pharma/biotech and CROs were:
56% of clinical trial sites do NOT deliver the expected number of patients
It takes Pharma an average of 6.46 weeks to identify sites, compared to 2 days with best in class offerings,
despite this only 32% are unsatisfied with waiting this long
61% of respondents agreed that there were major challenges with finding good investigators in particular
regions however there was no consensus on where those regions were 84% of respondents from Pharma felt that early engagement with potential investigators would increase recruitment
rates and yet none were looking into early engagement
Candice Yarde, VP of Business Development, DrugDev.org said,“The results of the survey ran the full gamut
from mundane and predictable through to surprising and even shocking. The
relatively high level of satisfaction with existing processes, despite lagging timelines and high rates of site underperformance, highlights a worrying disconnect between senior R&D
leadership,which is demanding transformational improvement and project teams that
have come to accept historical performance as standard.”
Earlier this year, DIA provided companies the opportunity to submit an application detailing how they
embodied the characteristics of “collaboration” and “innovation” and how they fostered th
ose characteristics in their offerings. A DIA panel reviewed the applications and selected five winning entrepreneurs,
including DrugDev.org to showcase their work in the Entrepreneur Pavilion in Booth 1709.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.